What Are Bayer's M&A Opportunities?
July 16 (Bloomberg) -- Bloomberg Industries' Sam Fazeli examines M&A opportunities for Bayer, moves in the overall pharmaceutical market and the Chinese government's probe into Glaxo Smithkline. He speaks on Bloomberg Television's "The Pulse."
Most Recent Videos
Teva Said Close to Closing $40.5 Billion Allergan Deal
20:22 - The U.S. Federal Trade Commission is close to signing off on Teva Pharmaceutical's deal to buy Allergan Plc's generics unit for $40.5 billion according to people familiar with the matter. Bloomberg's Elliot Gotkine reports on "Bloomberg Markets Middle East." (Source: Bloomberg)